The Lateral Metalation of Isoxazolo[3,4-d]pyridazinones towards Hit-to-Lead Development of Selective Positive Modulators of Metabotropic Glutamate Receptors
暂无分享,去创建一个
[1] Suwen Zhao,et al. G protein-coupled receptors: structure- and function-based drug discovery , 2021, Signal Transduction and Targeted Therapy.
[2] S. Cuzzocrea,et al. Role of Metabotropic Glutamate Receptors in Neurological Disorders , 2019, Front. Mol. Neurosci..
[3] Julie L. Engers,et al. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. , 2018, ACS medicinal chemistry letters.
[4] D. Backos,et al. Isoxazolo[3,4-d]pyridazinones positively modulate the metabotropic glutamate subtypes 2 and 4. , 2018, Bioorganic & medicinal chemistry.
[5] Sun Choi,et al. Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design , 2018, Front. Pharmacol..
[6] U. Grohmann,et al. Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4 , 2018, Expert opinion on drug discovery.
[7] K. Gregory,et al. Molecular insights into allosteric modulation of Class C G protein-coupled receptors. , 2017, Pharmacological research.
[8] David E. Gloriam,et al. Structural insight to mutation effects uncover a common allosteric site in class C GPCRs , 2016, Bioinform..
[9] K. Gregory,et al. Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. , 2016, Chemical reviews.
[10] Julie L. Engers,et al. Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. , 2015, Journal of medicinal chemistry.
[11] Zhiwei Feng,et al. Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family , 2015, The AAPS Journal.
[12] Paul J. Harrison,et al. The role of group II metabotropic glutamate receptors in cognition and anxiety: Comparative studies in GRM2−/−, GRM3−/− and GRM2/3−/− knockout mice , 2015, Neuropharmacology.
[13] N. Garg,et al. Pyridynes and indolynes as building blocks for functionalized heterocycles and natural products. , 2015, Chemical communications.
[14] J. Giraldo,et al. Overlapping binding sites drive allosteric agonism and positive cooperativity in type 4 metabotropic glutamate receptors , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] Jens Meiler,et al. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders , 2014, Nature Reviews Drug Discovery.
[16] R. Stevens,et al. Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.
[17] C. Campana,et al. 3-(1,3-Diphenylpropan-2-yl)-4-methyl-6-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one , 2013, Acta crystallographica. Section E, Structure reports online.
[18] G. Fisone,et al. Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease , 2013, Neuropharmacology.
[19] Marvin Waldman,et al. Lions and tigers and bears, oh my! Three barriers to progress in computer-aided molecular design , 2011, Journal of Computer-Aided Molecular Design.
[20] A. Scilimati,et al. Synthesis of N,N-dialkylaminobenzonitriles and halo-(N,N-dialkyl)benzamidines by reaction of halobenzonitriles with lithium amides , 2011 .
[21] A. Robichaud,et al. Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics. , 2011, ACS chemical neuroscience.
[22] Dan S. Tawfik,et al. Evolutionary optimization of computationally designed enzymes: Kemp eliminases of the KE07 series. , 2010, Journal of molecular biology.
[23] P. Conn,et al. Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.
[24] C. Vergelli,et al. Further studies on arylpiperazinyl alkyl pyridazinones: discovery of an exceptionally potent, orally active, antinociceptive agent in thermally induced pain. , 2009, Journal of medicinal chemistry.
[25] Jianpeng Ma,et al. CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..
[26] A. Scilimati,et al. Effect of the aryl group substituent in the dimerization of 3-arylisoxazoles to syn 2,6-diaryl-3,7-diazatricyclo[4.2.0.02,5]octan-4,8-diones induced by LDA , 2008 .
[27] Lisa Yan,et al. Fully Automated Molecular Mechanics Based Induced Fit Protein-Ligand Docking Method , 2008, J. Chem. Inf. Model..
[28] Eric A. Althoff,et al. Kemp elimination catalysts by computational enzyme design , 2008, Nature.
[29] C. Ghelardini,et al. 4-amino-5-substituted-3(2H)-pyridazinones as orally active antinociceptive agents: synthesis and studies on the mechanism of action. , 2007, Journal of medicinal chemistry.
[30] C. Vergelli,et al. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction. , 2006, Journal of medicinal chemistry.
[31] N. R. Natale,et al. Catalytic asymmetric synthesis of glutamate analogues. , 2004, Organic letters.
[32] Mei Bai,et al. Dimerization of G-protein-coupled receptors: roles in signal transduction. , 2004, Cellular signalling.
[33] M. Scheideler,et al. 4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity. , 2003, Farmaco.
[34] C. Ghelardini,et al. [(3-Chlorophenyl)piperazinylpropyl]pyridazinones and analogues as potent antinociceptive agents. , 2003, Journal of medicinal chemistry.
[35] David A. Case,et al. Effective Born radii in the generalized Born approximation: The importance of being perfect , 2002, J. Comput. Chem..
[36] M. C. Castellana,et al. Isoxazolo[3,4-d]pyridazinones and analogues as Leishmania mexicana PDE inhibitors. , 2002, Farmaco.
[37] V. D. Piaz,et al. Synthesis and Evaluation of Some Pyrazolo[3,4-d]pyridazinones and Analogues as PDE 5 Inhibitors Potentially Useful as Peripheral Vasodilator Agents , 2002, Journal of enzyme inhibition and medicinal chemistry.
[38] B. Twamley,et al. An improved procedure for the lateral lithiation of ethyl 4-acetyl-5-methyl-3-isoxazolyl carboxylate ☆ , 2001 .
[39] F. Fanelli,et al. Phenylpiperazinylalkylamino substituted pyridazinones as potent alpha(1) adrenoceptor antagonists. , 2001, Journal of medicinal chemistry.
[40] G. Rastelli,et al. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. , 1999, Journal of medicinal chemistry.
[41] N. R. Natale,et al. Lateral lithiation of ethyl 4-acetyl-5-methyl-3-isoxazolyl carboxylate with 5,5-dimethyl-1,3-dioxanyl as a directing group , 1998 .
[42] F. Fanelli,et al. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-ones and their corresponding 4,5-disubstituted-3-(2H)-pyridazinone analogues as new substrates for alpha1-adrenoceptor selective antagonists: synthesis, modeling, and binding studies. , 1998, Bioorganic & medicinal chemistry.
[43] Y. Mirzaei,et al. The Lateral Metalation of Isoxazoles. A Review. , 1995 .
[44] Y. Mirzaei,et al. THE LATERAL METALATION OF ISOXAZOLES. A REVIEW , 1993 .
[45] T. Torroba,et al. Solid State Photodimerization Reaction of Some 3‐Styrylisoxazolo‐(3,4‐d)pyridazin‐7(6H)‐ones. , 1987 .
[46] H. Hope,et al. Metalation of isoxazolyloxazolines, a facile route to functionally complex isoxazoles: utility, scope, and comparison to dianion methodology , 1985 .
[47] V. D. Piaz,et al. New functionalized pyrazoles from isoxazolopyridazinones , 1985 .
[48] C. Niou,et al. A facile synthesis of functionally complex isoxazole derivatives , 1985 .
[49] S. Pinzauti,et al. Condensation of some 3‐methylisoxazolo[3,4‐d]pyridazin‐7(6H)ones with aromatic aldehydes , 1976 .
[50] D. Kemp,et al. Physical organic chemistry of benzisoxazoles. II. Linearity of the Broensted free energy relation for the base-catalyzed decomposition of benzisoxazoles , 1973 .
[51] D. Kemp,et al. Physical organic chemistry of benzisoxazoles. I. Mechanism of the base-catalyzed decomposition of benzisoxazoles , 1973 .
[52] R. Micetich,et al. Studies in isoxazole chemistry. III. The preparation and lithiation of 3,5-disubstituted isoxazoles , 1970 .
[53] John D. Roberts,et al. Rearrangement in the Reaction of Chlorobenzene-1-C^(14) with Potassium Amide , 1953 .
[54] David E. Gloriam,et al. Generic GPCR residue numbers - aligning topology maps while minding the gaps. , 2015, Trends in pharmacological sciences.
[55] Ajay N. Jain,et al. Does your model weigh the same as a Duck? , 2011, Journal of Computer-Aided Molecular Design.
[56] Arthur Christopoulos,et al. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.
[57] V. D. Piaz,et al. 4,5-Functionalized 6-phenyl-3(2H)-pyridazinones: synthesis and evaluation of antinociceptive activity , 1996 .
[58] T. Torroba,et al. Solid State Photodimerisation Reaction of Some 3-Styrylisoxazolo[3,4-d]pyrida-zin-7(6H)-ones , 1986 .
[59] C. Niou,et al. Synthesis, metalation and electrophilic quenching of alkyl-isoxazole-4-tertiary carboxamides: a critical comparison of three isoxazole lateral metalation methods , 1986 .
[60] V. D. Piaz,et al. 1,2,3,4-Tetrahydro-1,2-diazepine derivatives from isoxazolo[3,4-d]pyridazin-7(6H)-ones , 1984 .